Digital mammography breast density estimates compared with standard-dose mammography.
Automated estimates of breast density made from synthetic digital mammograms is comparable to those from standard-dose mammograms, according to a study published in Radiology.
Researchers from the University of Pennsylvania in Philadelphia undertook a study to evaluate agreement between automated estimates of breast density made from standard-dose versus synthetic digital mammograms in a large cohort of women undergoing screening.
The study included 3,668 negative (Breast Imaging Reporting and Data System category 1 or 2) digital breast tomosynthesis (DBT) screening examinations consecutively performed over a four-month period. Both standard-dose and synthetic mammograms were available for analysis and were retrospectively analyzed.
The “For Presentation” standard-dose mammograms and synthetic images were analyzed by using a fully automated algorithm. Agreement between density estimates was assessed by using Pearson correlation, linear regression, and Bland-Altman analysis. Differences were evaluated by using the paired Student t test.
The results showed that breast percentage density (PD) estimates from synthetic and standard-dose mammograms were highly correlated (r = 0.92, P < .001), and the 95% Bland-Altman limits of agreement between PD estimates were −6.4% to 9.9%. The synthetic mammograms had PD estimates an average of 1.7% higher than standard-dose mammograms), with a larger disagreement by 1.56% in women with highly dense breast tissue.
The researchers concluded that fully automated estimates of breast density made from synthetic mammograms were generally comparable to those made from standard-dose mammograms. This finding could be important, they wrote. As clinicians strive to reduce radiation doses in screening mammograms, standard two-dimensional mammographic images are increasingly being replaced by synthetic mammograms in DBT screening.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.